HOME >> MEDICINE >> NEWS
Long-term outcomes for prostate cancer show IMRT Curative: 89 percent disease-free 8 years later

NEW YORK, September 27, 2006 -- Results from the largest study of men with prostate cancer treated with high-dose, intensity modulated radiation therapy (IMRT) show that the majority of patients remain alive with no evidence of disease after an average follow-up period of eight years. The 561 prostate cancer patients treated with IMRT at Memorial Sloan-Kettering Cancer Center were classified into prognostic risk groups. After an average of eight years, 89 percent of the men in the favorable risk group were disease-free and none of the men in any group developed secondary cancers as a result of the radiation therapy. This report, published in the October 2006 issue of The Journal of Urology, is the first description of long-term outcomes for prostate cancer patients using IMRT.

"Our results suggest that IMRT should be the treatment of choice for delivering high-dose, external beam radiotherapy for patients with localized prostate cancer," said Dr. Michael J. Zelefsky, Chief of the Brachytherapy Service at Memorial Sloan-Kettering. "We were able to show long-term safety and long-term efficacy in a very diverse group of prostate cancer patients that we followed many for as long as ten years. Despite the fact that some patients had an aggressive form of their disease with high Gleason scores and PSA (prostate specific antigen) levels, the overwhelming majority of patients had good tumor control with neither recurrence of their original cancer nor development of second cancers, which one might have expected from the high doses of radiation," he added. Pre-treatment diagnostic evaluations were performed for all of the patients to better define their clinically localized prostate cancer. They were classified into prognostic risk groups as defined by the National Comprehensive Cancer Network guidelines (www.nccn.org). These are based on clinical characteristics including age, T stage, Gleason score, PSA level, and pre-treatm
'"/>

Contact: Joanne Nicholas
nicholaj@mskcc.org
212-639-3137
Memorial Sloan-Kettering Cancer Center
27-Sep-2006


Page: 1 2

Related medicine news :

1. Long-term treatment with VYVANSE, first prodrug stimulant, demonstrates significant efficacy in ADHD
2. Long-term anti-clotting therapy sweetens stenting outcomes in diabetic patients
3. Long-term aspirin use associated with reduced risk of dying in women
4. Long-term data on safety and effectiveness of antiobesity drugs needed
5. Long-term financial costs associated with prostate cancer treatment
6. Long-term effects of non-alcoholic fatty liver disease
7. Long-term abstinence may resolve many of the neurocognitive deficits associated with alcoholism
8. Long-term safety results released for breast cancer drugs
9. Long-term ibuprofen regimen after brain injury worsens cognition in animal study
10. Media availability: Long-term survival of heart attack patients with shock
11. Long-term estrogen therapy linked to breast cancer risk

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/31/2020)... ... August 31, 2020 , ... Cardiothoracic surgeons ... biomedical engineers from Carnegie Mellon University (CMU) to develop a new heart monitoring ... undergone open heart surgery. , The AGH/CMU team was recently awarded a “Trailblazer” ...
(Date:8/31/2020)... ... August 31, 2020 , ... Ocean Springs, Mississippi-based pharmaceutical ... medical first responders across the United States. Since the start of the global ... (PPE) medical centers , hospitals , firefighters , and ...
(Date:8/31/2020)... ... August 31, 2020 , ... Colorado ... through high-quality, career-relevant, and affordable online education – is proud to announce its ... Among the first of its kind in the nation, the 60-credit hour program ...
(Date:8/31/2020)... ... ... A Cure for Covid-19 “PTS” with Mediation & Hypnosis , At this very turbulent ... panic, experiencing deep anxiety, immense stress, and right now are needing serious relief from a ... on the planet are experiencing a great degree of emotional discomfort, be it fear or ...
(Date:8/31/2020)... , ... August 31, 2020 , ... ... to improve outcomes for patients with advanced heart failure, today announced that the ... in the amount of $555,358 from the National Heart, Lung, and Blood Institute ...
Breaking Medicine News(10 mins):
(Date:8/31/2020)... AVIV, Israel (PRWEB) , ... August 31, 2020 ... ... to specialize in wellness-related technologies, today announced that they have invested $400,000 in ... competition that ran in collaboration with the Global Wellness Institute (GWI). , ...
(Date:8/28/2020)... ... ... Dr. Mark Surrey has been in practice for over 25 years. He ... the Department of OBGYN at UCLA’s David Geffen School of Medicine. , He ... is a Clinical Director of Fellowship Training for UCLA & Cedars Sinai Reproductive Endocrinology. ...
(Date:8/27/2020)... ... August 27, 2020 , ... Bleep LLC, maker of the DreamPort mask-less ... is the company’s new spokesperson. , “In my line of work, a good night ... the Bleep DreamPort it was a Bleeping no brainer for me,” said Jensen. “From ...
Breaking Medicine Technology:
Cached News: